Elena S. Mochalova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elena S. Mochalova has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Andrey V. Polosin
M.V. Lomonosov Moscow State University, National Anti-Doping Laboratory (Institute) (NADL MSU)
2 shared publications - Pavel V. Postnikov
National Anti‐Doping Laboratory (Institute) Lomonosov Moscow State University (NADL MSU) Moscow Russia
2 shared publications - Yuliya A. Efimova
MIREA – Russian Technological University (M.V. Lomonosov Institute of Fine Chemical Technologies)
2 shared publications - Alexander D. Askretkov
PHARMAPARK
1 shared publication - N. B. Savelieva
National Anti-Doping Laboratory (Institute), M.V. Lomonosov Moscow State University (NADL MSU)
1 shared publication - S. A. Kurbatkin
MIREA – Russian Technological University (M.V. Lomonosov Institute of Fine Chemical Technologies)
1 shared publication
Latest Publications
- Open Access
- 2 September 2025
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 20 (4) , 382-398
Semiquantitative determination of meldonium and emoxypine in human urine by HPLC–MS/MS after receiving a single therapeutic dose of Brainmax® and milk from cows receiving a preventive course of Emidonol®
Objectives. Emidonol® is a veterinary drug used to treat pathological conditions associated with hypoxia in cattle. In addition tomeldonium, which is included in the Prohibited List of the World Anti-Doping Agency, the biotransformation product of Emidonol® in animals is the antioxidant and antihypoxant emoxypine, which can act as a marker of contamination of food products with the above-mentioned widely known metabolic modulator. The study set out to semiquantitatively determine emoxypine and meldonium levels, as well as to compare the excretion profiles of these substances by high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) in urine samples of volunteers after receiving a single oral administration of a therapeutic dose of Brainmax® and after consuming a large amount of milk from cows that had received a prophylactic course of Emidonol®.Methods. Sample preparation of urine samples for the determination of meldonium was carried out using the “dilute and shoot” approach. Enzymatic hydrolysis with β-glucuronidase followed by purification by solid-phase extraction was used to determine emoxypine. Identification of meldonium and emoxypine was carried out by HPLC–MS/MS under conditions of electrospray ionization with registration of positively charged ions in the selective reaction monitoring (SRM) mode for the following transitions and collision energies: for meldonium, 147.1 > 147.1 (15), 147.1 > 132.1 (17), 147.1 > 58.1 (17), 147.1 > 59.1 (17), 147.1 > 42.1 (60); for emoxypine, 138.1 > 138.1 (7), 138.1 > 123.1 (15), 138.1 > 110.1 (20), 138.1 > 95.1 (20).Results. The possibility of simultaneous identifying meldonium and emoxypine obtained after enzymatic hydrolysis with β-glucuronidase in urine samples of volunteers after oral intake of single dose of Brainmax® and consuming a large amount of Emidonol®-contaminated milk using the HPLC–MS/MS method with different numbers and variants of SRM transitions was demonstrated. Differences in the excretion profiles of these substances were found after ingestion of large amounts of contaminated milk and a single oral dose of Brainmax® 15–18 h later and further. After taking contaminated milk 12 h or more later, emoxypine is detected in concentrations 5 or more times higher than meldonium concentrations and is excreted for a longer period of time. Conversely, after taking a single dose of Brainmax®, which contains both substances, the content of meldonium in urine samples of volunteers 15–18 h after taking it is several times higher in relation to emoxypine. The constant ratio of estimated concentrations of meldonium and emoxypine in Emidonol® was found to be approximately 1 : 2.Conclusions. Identification of meldonium in the presence of emoxypine in urine under certain conditions can be used to distinguish contamination of food products with a prohibited metabolic modulator from intentional ingestion of real doping.
- 2 September 2025
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 20 (4) , 382-398
Open AccessSemiquantitative determination of meldonium and emoxypine in human urine by HPLC–MS/MS after receiving a single therapeutic dose of Brainmax® and milk from cows receiving a preventive course of Emidonol®
Objectives. Emidonol® is a veterinary drug used to treat pathological conditions associated with hypoxia in cattle. In addition tomeldonium, which is included in the Prohibited List of the World Anti-Doping Agency, the biotransformation product of Emidonol® in animals is the antioxidant and antihypoxant emoxypine, which can act as a marker of contamination of food products with the above-mentioned widely known metabolic modulator. The study set out to semiquantitatively determine emoxypine and meldonium levels, as well as to compare the excretion profiles of these substances by high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) in urine samples of volunteers after receiving a single oral administration of a therapeutic dose of Brainmax® and after consuming a large amount of milk from cows that had received a prophylactic course of Emidonol®.Methods. Sample preparation of urine samples for the determination of meldonium was carried out using the “dilute and shoot” approach. Enzymatic hydrolysis with β-glucuronidase followed by purification by solid-phase extraction was used to determine emoxypine. Identification of meldonium and emoxypine was carried out by HPLC–MS/MS under conditions of electrospray ionization with registration of positively charged ions in the selective reaction monitoring (SRM) mode for the following transitions and collision energies: for meldonium, 147.1 > 147.1 (15), 147.1 > 132.1 (17), 147.1 > 58.1 (17), 147.1 > 59.1 (17), 147.1 > 42.1 (60); for emoxypine, 138.1 > 138.1 (7), 138.1 > 123.1 (15), 138.1 > 110.1 (20), 138.1 > 95.1 (20).Results. The possibility of simultaneous identifying meldonium and emoxypine obtained after enzymatic hydrolysis with β-glucuronidase in urine samples of volunteers after oral intake of single dose of Brainmax® and consuming a large amount of Emidonol®-contaminated milk using the HPLC–MS/MS method with different numbers and variants of SRM transitions was demonstrated. Differences in the excretion profiles of these substances were found after ingestion of large amounts of contaminated milk and a single oral dose of Brainmax® 15–18 h later and further. After taking contaminated milk 12 h or more later, emoxypine is detected in concentrations 5 or more times higher than meldonium concentrations and is excreted for a longer period of time. Conversely, after taking a single dose of Brainmax®, which contains both substances, the content of meldonium in urine samples of volunteers 15–18 h after taking it is several times higher in relation to emoxypine. The constant ratio of estimated concentrations of meldonium and emoxypine in Emidonol® was found to be approximately 1 : 2.Conclusions. Identification of meldonium in the presence of emoxypine in urine under certain conditions can be used to distinguish contamination of food products with a prohibited metabolic modulator from intentional ingestion of real doping.
- Open Access
- 3 November 2024
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 19 (5) , 393-407
Identification of hypoxene metabolites in urine samples using gas chromatography–tandem mass spectrometry for anti-doping control
Objectives. Hypoxen is a drug which possesses antioxidant and antihypoxic effects. It achieves this by increasing the utilization of oxygen by mitochondria, intensifying oxidative phosphorylation, and as a result, improving tissue respiration. Athletes take it during prolonged exercise, in order to increase efficiency and reduce physical overwork. Since 2023, the World Anti-Doping Agency has included the drug in the monitoring program, in the belief that it can be used to gain a competitive advantage. It is thus a candidate for inclusion in the Prohibited List as a potential regulator of the human metabolism. Currently, there are no studies or scientific publications focusing on the identification of hypoxene in biofluids for the purpose of anti-doping control. The aim of this study is to determine the possible metabolites of the drug and their chromato-mass spectrometric characteristics in urine samples using gas chromatography–tandem mass spectrometry (GC–MS/MS) for doping control screening purposes.Methods. Sample preparation of urine samples was carried out using enzymatic hydrolysis, liquid–liquid extraction and derivatization. The GC–MS/MS method was used for analysis. Screening of hypoxene metabolites was carried out in the mode of total ion current after fragmentation of selected parent ions.Results. Three specific metabolites of hypoxene (m/z 342, 300, and 346, including trimethylsilyl derivatives) were identified in urine samples of volunteers (n = 3). They can act as markers for taking the target antihypoxant, and their possible structural formulas are given. The excretion curves of two metabolites with an m/z of 300 and 346 respectively in urine were studied. The maximum concentration is reached after 8–14 and 1.5–6 h, respectively. It was established, that these metabolites are reliably identified in urine 90 h or more after a single dose of the drug.Conclusions. Possible structures of hypoxene metabolites in urine samples from volunteers were determined for the first time and their chromato-mass spectrometric characteristics were established. The approach developed in this study can be used for screening analysis of hypoxene for the purpose of anti-doping control.
- 3 November 2024
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 19 (5) , 393-407
Open AccessIdentification of hypoxene metabolites in urine samples using gas chromatography–tandem mass spectrometry for anti-doping control
Objectives. Hypoxen is a drug which possesses antioxidant and antihypoxic effects. It achieves this by increasing the utilization of oxygen by mitochondria, intensifying oxidative phosphorylation, and as a result, improving tissue respiration. Athletes take it during prolonged exercise, in order to increase efficiency and reduce physical overwork. Since 2023, the World Anti-Doping Agency has included the drug in the monitoring program, in the belief that it can be used to gain a competitive advantage. It is thus a candidate for inclusion in the Prohibited List as a potential regulator of the human metabolism. Currently, there are no studies or scientific publications focusing on the identification of hypoxene in biofluids for the purpose of anti-doping control. The aim of this study is to determine the possible metabolites of the drug and their chromato-mass spectrometric characteristics in urine samples using gas chromatography–tandem mass spectrometry (GC–MS/MS) for doping control screening purposes.Methods. Sample preparation of urine samples was carried out using enzymatic hydrolysis, liquid–liquid extraction and derivatization. The GC–MS/MS method was used for analysis. Screening of hypoxene metabolites was carried out in the mode of total ion current after fragmentation of selected parent ions.Results. Three specific metabolites of hypoxene (m/z 342, 300, and 346, including trimethylsilyl derivatives) were identified in urine samples of volunteers (n = 3). They can act as markers for taking the target antihypoxant, and their possible structural formulas are given. The excretion curves of two metabolites with an m/z of 300 and 346 respectively in urine were studied. The maximum concentration is reached after 8–14 and 1.5–6 h, respectively. It was established, that these metabolites are reliably identified in urine 90 h or more after a single dose of the drug.Conclusions. Possible structures of hypoxene metabolites in urine samples from volunteers were determined for the first time and their chromato-mass spectrometric characteristics were established. The approach developed in this study can be used for screening analysis of hypoxene for the purpose of anti-doping control.